Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Elevance Health Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Reportable Segments
- Enterprise Value (EV)
- Price to Earnings (P/E) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Elevance Health Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
The financial performance exhibits several distinct trends across the analyzed periods. The margins and returns show gradual shifts reflecting changes in profitability and asset utilization over time.
- Gross Profit Margin
- The gross profit margin demonstrates a declining trend from 19.38% in the first quarter of 2021 to 14.45% by the third quarter of 2025. The margin remains relatively stable between the mid-16% range from early 2022 through early 2024 but experiences a steady decrease thereafter. This suggests a continual erosion in the efficiency of core operations or increased cost pressures impacting direct costs relative to revenues.
- Operating Profit Margin
- The operating profit margin starts at 4.83% in early 2021, peaks at just over 5.15% towards the end of 2021, and then follows a gently declining path to 3.58% by late 2025. There is a minor stabilization around 4.5% to 4.7% during 2023-2024 before further softening. This pattern indicates that while operating efficiency held firm for some time, it gradually deteriorated, possibly reflecting increased operating expenses or reduced pricing leverage.
- Net Profit Margin
- The net profit margin shows a moderate increase from 3.82% in early 2021 to a peak near 4.46% at the end of 2021, followed by a slow but consistent downward trajectory to 2.86% by late 2025. Periods of relative stability occur around 3.5% to 3.9% between 2022 and early 2024 with subsequent decline thereafter. This decline points to diminishing bottom-line profitability, potentially due to higher tax burdens, interest expenses, or non-operating costs increasing over time.
- Return on Equity (ROE)
- ROE exhibits an upward movement from 13.92% in the initial quarter of 2021 reaching a high near 17.36% in early 2022, then trending downward to 12.59% by the third quarter of 2025. The ROE follows a general decline post-2022, with slight recoveries in mid-2024 but cannot maintain earlier levels. This trend indicates that shareholder returns have become less productive over time, which could be due to declining net earnings or increased equity base outpacing income growth.
- Return on Assets (ROA)
- ROA follows a similar pattern with growth from 4.93% at the start of 2021 to about 6.26% at the end of 2021, then gradually falls to 4.51% by late 2025. After peaking in 2021, asset efficiency in generating profits diminishes progressively. Despite small fluctuations, the overall reduction points toward less effective use of assets to generate net income in recent years.
In summary, the data reflects strong profitability and efficiency indicators during 2021, followed by a period of relative stability in 2022 and 2023. From 2024 onwards, there is a gradual and persistent decline in profit margins and returns, suggesting intensifying cost pressures, weakening operational performance, or external market challenges impacting profitability and capital efficiency.
Return on Sales
Return on Investment
Gross Profit Margin
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Gross profit | |||||||||||||||||||||||||
| Operating revenue | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Gross profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Gross profit margin = 100
× (Gross profitQ3 2025
+ Gross profitQ2 2025
+ Gross profitQ1 2025
+ Gross profitQ4 2024)
÷ (Operating revenueQ3 2025
+ Operating revenueQ2 2025
+ Operating revenueQ1 2025
+ Operating revenueQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data reveals several notable trends across the reported quarters.
- Gross Profit
- Gross profit exhibits a fluctuating pattern throughout the periods. Initial quarters show values around 6,000 million USD, followed by a rise peaking at approximately 7,630 million USD in the first quarter of 2023. Subsequent quarters reveal a decline toward the end of 2023 and 2024, with a particular low near 5,477 million USD in the last quarter of 2024 before partially recovering to 8,470 million USD in the first quarter of 2025. Overall, the trend suggests volatility with several peaks and troughs rather than steady growth.
- Operating Revenue
- Operating revenue demonstrates a generally upward trajectory. Beginning at around 32,098 million USD in the first quarter of 2021, revenue rises steadily through the years, reaching nearly 50,087 million USD by the first quarter of 2025. This indicates consistent growth in sales or service income across the observed timeline, suggesting an expanding scale of operations.
- Gross Profit Margin
- The gross profit margin shows a declining trend over the evaluated periods. Initially near 19.38% in early 2021, the margin steadily decreases, falling below 17% throughout most quarters in the middle timeframe, and continuing downward to about 14.45% by the first quarter of 2025. This decline indicates increasing cost pressure or reduced pricing power relative to operating revenue, leading to shrinking profitability per revenue dollar.
In summary, while operating revenue has grown markedly, gross profit and gross profit margin data reveal challenges with maintaining profitability levels, with margins decreasing despite higher revenue. The variability in gross profit combined with the margin contraction may warrant further investigation into cost structures, pricing strategies, or changes in the product/service mix affecting overall financial performance.
Operating Profit Margin
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Operating income | |||||||||||||||||||||||||
| Operating revenue | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Operating profit margin = 100
× (Operating incomeQ3 2025
+ Operating incomeQ2 2025
+ Operating incomeQ1 2025
+ Operating incomeQ4 2024)
÷ (Operating revenueQ3 2025
+ Operating revenueQ2 2025
+ Operating revenueQ1 2025
+ Operating revenueQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data reflects several noteworthy trends over the observed periods concerning operating income, operating revenue, and operating profit margin.
- Operating Income
- Operating income exhibits a generally cyclical pattern with notable fluctuations quarterly. Initial quarters show relatively strong values with occasional dips, such as a pronounced decrease towards the end of 2021 followed by recovery in early 2022. A similar pattern repeats in 2023 and 2024, but the amplitude of the fluctuations appears to increase in the later years. For example, after peaking around early 2024, operating income sharply declines in the subsequent quarters, hitting one of the lowest points by the end of 2024, before partially rebounding in early 2025. Overall, there is no consistent long-term upward or downward trend, but significant volatility is present in operating income levels.
- Operating Revenue
- Operating revenue demonstrates a clear upward trend throughout the periods. Starting from approximately 32,000 million US dollars in early 2021, the revenue grows steadily across most quarters, reaching over 50,000 million US dollars by early 2025. Growth is consistent with only minor slowdowns or plateaus observed, particularly around 2023 to early 2024, where revenue levels off briefly before continuing upward again. This steady increase indicates expanding business scale or enhanced revenue-generating activity over time.
- Operating Profit Margin
- The operating profit margin reflects a subtle but discernible downward trend over the examined periods. Starting just below 5% in 2021, the margin slightly fluctuates but generally declines towards approximately 3.5% by early 2025. This decrease suggests either rising costs relative to revenues or a decreasing efficiency in converting revenue to profit. The margin shows a pattern of minor recovery following dips but never regains the initial higher margin levels, implying persistent pressure on profitability.
In summary, while operating revenue steadily increases, supporting business growth, operating income fluctuates significantly without a clear upward trajectory, and operating profit margin declines gradually, indicating challenges in sustaining profit efficiency amid growing revenue. These patterns highlight potential areas for management attention, particularly regarding cost control and profitability enhancement amidst expanding operations.
Net Profit Margin
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Shareholders’ net income | |||||||||||||||||||||||||
| Operating revenue | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Net profit margin = 100
× (Shareholders’ net incomeQ3 2025
+ Shareholders’ net incomeQ2 2025
+ Shareholders’ net incomeQ1 2025
+ Shareholders’ net incomeQ4 2024)
÷ (Operating revenueQ3 2025
+ Operating revenueQ2 2025
+ Operating revenueQ1 2025
+ Operating revenueQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial performance evidenced over the observed quarters reflects discernible fluctuations in key metrics, including shareholders’ net income, operating revenue, and net profit margin.
- Shareholders’ Net Income
- The net income shows variability across the periods. Initial quarters in 2021 reveal moderate income levels, peaking at 1,793 million US dollars in the second quarter before a decline towards the end of the year. In 2022, net income experienced instability with a notable dip in the fourth quarter down to 949 million. The first quarter of 2023 recorded a rebound to 1,989 million US dollars, followed by decreases in subsequent quarters. In 2024, the first two quarters improved substantially, reaching as high as 2,300 million, but again declined notably by the end of the year. Early 2025 exhibits a reduction with figures trailing below 1,750 million. This pattern indicates cyclical volatility with peaks in early and mid-year periods and troughs towards the end of each year.
- Operating Revenue
- Operating revenue displays a generally upward trajectory throughout the examined timeframe. Beginning from approximately 32,000 million US dollars in early 2021, revenue steadily increases quarter-over-quarter, reaching a level exceeding 50,000 million US dollars by the first quarter of 2025. Despite minor short-term declines or plateaus, the overall trend suggests consistent growth in top-line performance, reflecting expanding business operations or market penetration.
- Net Profit Margin
- The net profit margin percentage reveals a mildly declining trend over the periods. The initial quarter margin stood close to 3.8%, fluctuating modestly around this level through 2021 and 2022 with minor peaks above 4.4%. From 2023 onwards, the margin diminishes gradually to values near or below 3%, with the lowest points observed in mid to late 2025. This contraction in profitability relative to revenue growth suggests increasing cost pressures or changes in the operational environment affecting the efficiency or expense management.
In summary, the company's operating revenue has grown steadily over the quarters, indicating successful revenue generation. However, shareholders’ net income has been subject to notable volatility, with pronounced fluctuations implying potential variability in earnings quality or other influencing factors. Concurrently, the net profit margin shows a declining trend, which may signal emerging challenges in maintaining profitability despite higher revenues. These dynamics warrant close monitoring to ensure sustained financial health and operational efficiency.
Return on Equity (ROE)
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Shareholders’ net income | |||||||||||||||||||||||||
| Shareholders’ equity | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROE1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
ROE = 100
× (Shareholders’ net incomeQ3 2025
+ Shareholders’ net incomeQ2 2025
+ Shareholders’ net incomeQ1 2025
+ Shareholders’ net incomeQ4 2024)
÷ Shareholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial performance over the analyzed quarters shows distinct patterns in net income, equity, and return on equity (ROE), reflecting varying profitability and capital efficiency across the timeline.
- Shareholders’ Net Income
-
The net income exhibits a cyclical pattern with noticeable fluctuations. There is an initial rise from 1665 million to a peak of 1793 million early in the first year, followed by a decline down to 1137 million by the end of the year. The subsequent period sees an increase reaching nearly 1805 million, then a decline to 949 million toward the end of 2022. Throughout 2023 and into 2024, net income peaks again significantly, reaching as high as 2300 million and 2246 million in respective quarters. However, it declines sharply later in the 2024 and 2025 quarters, bottoming out at 418 million before partially recovering to 1189 million. This volatility suggests exposure to variable income factors, possibly external economic conditions or internal operational influences.
- Shareholders’ Equity
-
Shareholders’ equity has demonstrated a steady growth trajectory throughout the period. Starting at 33,853 million, it gradually increased with minor fluctuations, reaching a high of 43,775 million by the third quarter of 2024. There is a slight dip in the fourth quarter of 2024 but rebounds quickly in 2025, ending roughly around 43,953 million. This consistent growth in equity suggests reinvestment of earnings, issuance of new shares, or retained earnings accumulation supporting the company's capital base.
- Return on Equity (ROE)
-
ROE shows a generally downward trend over the observed periods. Initially, it starts at a moderate 13.92%, peaks at about 17.36% mid-2022, indicating efficient use of equity to generate profits during that time. Following this peak, there is a gradual decline throughout late 2023 and 2024, moving from approximately 16.62% down to around 14.47%. It continues to fall in 2025, reaching a low near 12.26%, before a slight increase toward the end. The decreasing ROE trend despite growing equity and fluctuating net income might reflect diminishing profit margins or increasing equity base outpacing net income growth.
In summary, shareholders’ net income manifests significant volatility with strong peaks and troughs, while shareholders' equity increases steadily overall, suggesting solid capital foundation growth. ROE indicates a decreasing trend implying potential challenges in sustaining profit efficiency relative to equity. These insights could inform a focus on stabilizing income sources and optimizing return on invested capital moving forward.
Return on Assets (ROA)
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Shareholders’ net income | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROA1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
ROA = 100
× (Shareholders’ net incomeQ3 2025
+ Shareholders’ net incomeQ2 2025
+ Shareholders’ net incomeQ1 2025
+ Shareholders’ net incomeQ4 2024)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analyzed financial data reveals several noteworthy trends related to the company’s net income, total assets, and return on assets (ROA) over multiple quarters.
- Shareholders’ Net Income
- Net income exhibits considerable volatility across the observed periods. There are peaks notably around the first quarter of 2024 (US$2246 million) and the first quarter of 2023 (US$1989 million), indicating strong profitability in these quarters. However, sizable declines follow in subsequent quarters, for example in the fourth quarter of 2024 (US$418 million), which reflects fluctuations in earnings that could be tied to seasonal factors, market conditions, or internal operational changes. Despite the volatility, there is no consistent upward or downward trend over the entire time span.
- Total Assets
- Total assets show a steady and gradual increase over time, growing from approximately US$95,683 million initially to about US$122,749 million by the end of the period analyzed. This consistent rise suggests ongoing asset accumulation or investment, which may support future growth or reflect capital expenditures and acquisitions. No significant asset reductions are noticeable, indicating stable asset management.
- Return on Assets (ROA)
- The ROA metric demonstrates a moderate declining trend from around 6.26% at the end of 2021 to values closer to 4.4%–4.5% by mid to late 2025. While there are minor fluctuations, the overall trajectory points to decreased efficiency in generating profit from the asset base over time. This decline could stem from the increasing asset base not being matched by proportional increases in net income or changes in operational effectiveness.
In summary, the company’s total assets are expanding steadily, while net income shows marked quarterly variability without a clear directional trend. Meanwhile, ROA declines moderately, suggesting a need to assess the efficiency of asset utilization in generating earnings going forward.